Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is a biopharmaceutical company with a promising pipeline focused on developing treatments for neurodegenerative diseases. Their lead product, ZUNVEYL® (benzgalantamine), has shown strong commercial potential with positive clinical data and promising real-world evidence supporting its use. The company's recent financial results have also been impressive, with solid revenue growth and a strong cash position to support future growth and development. With a seasoned and experienced management team and the potential for expanding into new indications and formulations, Alpha Cognition is positioned for success in the long-term.

Bears say

Alpha Cognition is currently conducting multiple post-approval clinical trials for their lead product, ZUNVEYL, with promising real-world evidence in the BEACON study expected to conclude and provide important data next quarter. However, there are risks to consider, including the potential for slower market uptake of ZUNVEYL and setbacks in clinical testing, which could lead to dilution risks in the medium to long-term. Overall, while there is potential for success, there are also significant risks that could impact the company's financials and stock price in the future. - As mentioned, Alpha Cognition's current focus is on their lead product, ZUNVEYL, with expected peak annual sales of $540M in the US and a 12-month price objective of $18 per share. However, risks such as slower market uptake and setbacks in clinical testing could impact these projections. Overall, the company's financials and stock price are at risk due to these factors, making it a negative outlook for investors. This is not financial advice, only an analysis based on public information.

ACOG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 5 analysts, ACOG has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.